MPG.eBooks - Description: Clinical review report: Lanadelumab (Takhzyro) (Shire pharma Canada ULC)

Cover Image

Read Now

Clinical review report: Lanadelumab (Takhzyro) (Shire pharma Canada ULC) indication : for routine prevention of attacks of hereditary angioedema in adolescents and adults

The objective of this review is to evaluate the beneficial and harmful effects of lanadelumab for the routine prevention of attacks of hereditary angioedema in adolescents and adults

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2020, January 2020
Series:	CADTH common drug review
Subjects:	Adult Canada Antibodies, Monoclonal / Therapeutic Use Angioedemas, Hereditary / Drug Therapy Adolescent Angioedemas, Hereditary / Prevention & Control
Online Access:	http://www.ncbi.nlm.nih.gov/books/NBK558612
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The objective of this review is to evaluate the beneficial and harmful effects of lanadelumab for the routine prevention of attacks of hereditary angioedema in adolescents and adults
Item Description:	"Final (with redactions)."
Physical Description:	1 PDF file (122 pages) illustrations